215309-01-6

Basic information

• Product Name: 3-(4-Methylpiperazin-1-yl)benzoic acid
• Synonyms: 3-(4-METHYLPIPERAZIN-1-YL)BENZOIC ACID;AKOS BB-5295;3-(4-Methylpiperazin-1-yl)Benz;1-(3-Carboxyphenyl)-4-methylpiperazine;3-(4-Methyl-1-piperazinyl)benzoic acid
• CAS NO: 215309-01-6
• Molecular Formula: C₁₂H₁₆N₂O₂
• Molecular Weight: 220.27
• Product Categories: Acids and Derivatives;Amines and Anilines;API intermediates;Piperazidine intermediates;Piperazines
• Mol File: 215309-01-6.mol
• Article Data: 3

Chemical Properties

• Melting Point: 187-190 °C
• Boiling Point: 400.2 °C at 760 mmHg
• Flash Point: 195.8 °C
• Appearance: /
• Density: 1.188 g/cm³
• Vapor Pressure: 4.02E-07mmHg at 25°C
• Refractive Index: 1.579
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 3-(4-Methylpiperazin-1-yl)benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-Methylpiperazin-1-yl)benzoic acid(215309-01-6)
• EPA Substance Registry System: 3-(4-Methylpiperazin-1-yl)benzoic acid(215309-01-6)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36/37/38
• Safety Statements: 22-26-36/37/39
• Hazardous Substances Data: 215309-01-6(Hazardous Substances Data)

Usage

General Description

3-(4-Methylpiperazin-1-yl)benzoic acid, also known as 4-Methylpiperazin-1-yl)benzoic acid, is a chemical compound with the molecular formula C13H17N3O2. It is used in the pharmaceutical industry as an intermediate in the synthesis of various drugs, including antipsychotics and antidepressants. The compound is a derivative of benzoic acid and contains a piperazine ring, which makes it a potential target for drug design and development. Its role as a pharmaceutical intermediate highlights its importance in the field of medicinal chemistry and drug discovery.

InChI:InChI=1/C12H16N2O2/c1-13-5-7-14(8-6-13)11-4-2-3-10(9-11)12(15)16/h2-4,9H,5-8H2,1H3,(H,15,16)

Upstream product

• 51-75-2 nitrogen mustard 
• 474334-89-9 methyl 3-(4-methylpiperazin-1-yl)benzoate 
• 251457-29-1 3-(4-Methylpiperazinyl)-benzoic acid tert-butyl ester 
• 99-05-8 meta-aminobenzoic acid 
• 849753-22-6 3-(4-methyl-piperazin-1-yl)-benzoic acid butyl ester 

Downstream Products

• 709044-21-3 4-[3-(4-methyl-piperazin-1-yl)-benzoylamino]-benzoic acid methyl ester 
• 1055925-78-4 N'-{2-cyano-9-[3-(dimethylamino)propyl]-9H-purin-6-yI}-N'-cyclopentyl-3-(4-methyl-1-piperazinyl)benzohydrazide trifluoroacetate 
• 1055925-75-1 N'-(2-cyano-9-methyl-9H-purin-6-yI)-N'-cyclohexyl-3-(4-methyl-1-piperazinyl)benzohydrazide trifluoroacetate 
• 1055925-66-0 N'-(2-cyano-9-methyl-9H-purin-6-yI)-N'-cyclopentyl-3-(4-methyl-1-piperazinyl)benzohydrazide trifluoroacetate 
• 1055925-77-3 N'-{2-cyano-9-[3-(dimethylamino)propyl]-9H-purin-6-yI}-N'-cyclopentyl-3-(4-methyl-1-piperazinyl)benzohydrazide 
• 1055925-88-6 N'-{2-cyano-9-[2-(dimethylamino)ethyl]-9H-purin-6-yl}-N'-cyclopentyl-3-(4-methyl-1-piperazinyl)benzohydrazide 
• 1055925-74-0 N'-(2-cyano-9-methyl-9H-purin-6-yI)-N'-cyclohexyl-3-(4-methyl-1-piperazinyl)benzohydrazide 
• 1055925-65-9 N'-(2-cyano-9-methyl-9H-purin-6-yI)-N'-cyclopentyl-3-(4-methyl-1-piperazinyl)benzohydrazide 
• 1616960-87-2 N-(2-(2-methyl-1H-indol-1-yl)ethyl)-3-(4-methylpiperazin-1-yl)benzamide 
• 1422207-83-7 C₃₀H₃₈N₄O₂ 
• 1055927-86-0 3-(4-methyl-1-piperazinyl) benzoyl chloride 

Relevant articles and documents

PURINES AS CYSTEINE PROTEASE INHIBITORS

Substituted heteroaryl nitrile derivatives of Formula I, processes for their preparation, pharmaceutical compositions comprising such compounds and use of the compounds as cysteine protease inhibitors are provided.

Protease inhibitors

The present invention provides bis-aminomethyl carbonyl protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.